Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | DGKA | P23743 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5423152 | 0.85 | LMNA (0.49) | MAPTLMNAFFAR1FFAR4DGKA | |
| SCHEMBL29227003 | 0.83 | LMNA (0.51) | MAPTLMNAFFAR1FFAR4DGKA | |
| SCHEMBL28233784 | 0.80 | LMNA (0.55) | MAPTLMNADGKAMEN1KMT2A | |
| SCHEMBL7882764 | 0.80 | FFAR4 (0.59) | MAPTLMNAFFAR1FFAR4DGKA | |
| SCHEMBL19065763 | 0.80 | LMNA (0.51) | MAPTLMNADGKAMEN1KMT2A | |
| SCHEMBL27722265 | 0.79 | LMNA (0.50) | MAPTLMNADGKAMEN1KMT2A | |
| SCHEMBL17371719 | 0.79 | ENPP2 (0.47) | MAPTLMNAKDM4EDUSP3 | |
| SCHEMBL29373663 | 0.78 | LMNA (0.53) | MAPTLMNADGKAMEN1KMT2A | |
| SCHEMBL29373377 | 0.78 | LMNA (0.53) | MAPTLMNADGKAMEN1KMT2A | |
| SCHEMBL29374305 | 0.78 | LMNA (0.53) | MAPTLMNADGKAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221853-B2 | Glyphosate dimethylamine salt crystal, preparation method and use thereof | ZHEJIANG WYNCA CHEMICAL INDUSTRY GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20150307528-A1 | GLYPHOSATE DIMETHYLAMINE SALT CRYSTAL, PREPARATION METHOD AND USE THEREOF | ZHEJIANG WYNCA CHEMICAL INDUSTRY GROUP CO., LTD. (CN) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307528-A1 | GLYPHOSATE DIMETHYLAMINE SALT CRYSTAL, PREPARATION METHOD AND USE THEREOF | GNMT, GMNN, GMDS | MAPT 1516/4885LMNA 3196/4885FFAR1 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.